
About Prism Medico and Pharmacy Limited
Data last updated:
Prism Medico and Pharmacy Limited is a public limited company based in Kala Amb, Himachal Pradesh, India. It operates in the industrial chemicals segment of the chemicals and materials sector. It was incorporated on 22 March 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Himachal Pradesh, under CIN L24100HP2002PLC009299. Its GSTIN is 02AAACW0505H1Z0 (Himachal Pradesh). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 512217.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹13.56 Cr. It is led by directors including Sakshi Laller (Whole-Time Director) and Davender Singh.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Suketi Road, Kala Amb, Himachal Pradesh, India – 173030.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2.44 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹33 Lakh (net margin 13.5%) and EBITDA of ₹41 Lakh (EBITDA margin 16.8%). The net worth stands at ₹15.41 Cr (up 2.1% YoY). Total assets are valued at ₹15.41 Cr (up 2.1% YoY).
The company is associated with 1 brand: Prism Medico. Court records list 1 case involving the company, including 1 filed by the company. The company has 474 deals on record (474 market trades); the latest was in May 2026. The company has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 21 overdue payments to 1 micro and small supplier.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website prismmedico.com.
Company details
CIN history
Prism Medico and Pharmacy has 5 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100HP2002PLC009299, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100HP2002PLC009299 | Current |
| L51109HP2002PLC009299 | Previous |
| U51109WB2002PLC094419 | Previous |
| L51109MH2002PLC206595 | Previous |
| L51109WB2002PLC094419 | Previous |
| L51109PB2002PLC047444 | Previous |
Contact details
Prism Medico and Pharmacy Limited's registered office is in Kala Amb, Himachal Pradesh. Its website is prismmedico.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressSuketi Road, Kala Amb, Himachal Pradesh, India – 173030
- IndustryChemicals and Materials, Industrial Chemicals
To see the full contact details of Prism Medico and Pharmacy Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Prism Medico and Pharmacy operates one associated brand: Prism Medico. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Drugs for multiple therapeutic areas are manufactured through R&D efforts. | prismmedico.in |
Financials of Prism Medico and Pharmacy Limited
FY 2025-26 filings availablePrism Medico and Pharmacy Limited reported revenue of ₹2.44 Cr (up 287.3% YoY) for FY 2025-26.
Financial Highlights
FY 2018-19 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Income statement | |||
| Revenue | 54.43 | 22.80 | 5.27 |
| Revenue growth | +138.7% | +332.6% | - |
| EBITDA | 0.12 | 0.76 | 0.07 |
| EBITDA margin | +0.2% | +3.3% | +1.3% |
| Profit before tax | (0.07) | 0.06 | (0.21) |
| Net profit | 0.16 | (0.03) | (0.22) |
| Net profit margin | +0.3% | -0.1% | -4.2% |
| EPS (₹) | 0.07 | 0.00 | 0.00 |
| Balance sheet | |||
| Total assets | 15.21 | 15.07 | 16.38 |
| Net worth | 12.91 | 12.87 | 12.87 |
| Total debt | 2.27 | 2.18 | 3.50 |
| Cash & bank | 0.41 | 1.36 | 1.95 |
| Net working capital | 4.85 | 3.18 | 6.42 |
| Cash flow | |||
| Cash from operations | (0.44) | 3.55 | 0.00 |
| Cash from investing | 0.00 | (2.53) | 0.00 |
| Cash from financing | (0.50) | (1.61) | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2.44 | 0.63 | 2.93 | 1.27 | 8.44 | 16.76 | 26.89 |
| Revenue growth | +287.3% | -78.5% | +130.7% | -85.0% | -49.6% | -37.7% | - |
| EBITDA | 0.41 | (0.08) | (0.13) | (0.10) | (0.50) | (0.17) | (0.05) |
| EBITDA margin | +16.8% | -12.7% | -4.4% | -7.9% | -5.9% | -1.0% | -0.2% |
| Profit before tax | 0.44 | (0.06) | (0.03) | (0.11) | (0.51) | (0.18) | (0.07) |
| Net profit | 0.33 | (0.04) | (0.02) | (0.08) | (0.38) | (0.13) | (0.05) |
| Net profit margin | +13.5% | -6.4% | -0.7% | -6.3% | -4.5% | -0.8% | -0.2% |
| EPS (₹) | 0.53 | (0.08) | (0.04) | (0.13) | (0.61) | (0.21) | (0.08) |
| Balance sheet | |||||||
| Total assets | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.93 | 13.06 |
| Net worth | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.92 | 13.05 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.06 | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 |
| Net working capital | 15.25 | 14.83 | 14.89 | 14.92 | 12.32 | 10.86 | 11.04 |
| Cash flow | |||||||
| Cash from operations | 0.00 | (0.02) | (0.01) | 2.95 | (2.38) | (0.05) | (4.36) |
| Cash from investing | 0.00 | 0.00 | 0.00 | (2.91) | 2.35 | 0.02 | 4.36 |
| Cash from financing | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.18 | 0.00 | 0.28 | 0.07 | 0.50 | 1.59 | 0.07 | 0.21 |
| Revenue growth (YoY) | -64.0% | -100.0% | +300.0% | -66.7% | +72.4% | +2550.0% | - | - |
| Other income | 0.26 | 0.09 | 0.00 | 0.01 | 0.02 | 0.00 | 0.01 | 0.00 |
| Total expenses | 0.22 | 0.15 | 0.41 | 0.09 | 0.60 | 0.94 | 0.06 | 0.22 |
| EBITDA | (0.04) | (0.15) | (0.13) | (0.02) | (0.10) | 0.65 | 0.01 | (0.01) |
| EBITDA margin | -22.2% | - | -46.4% | -28.6% | -20.0% | +40.9% | +14.3% | -4.8% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.22 | (0.06) | (0.13) | (0.01) | (0.08) | 0.65 | 0.02 | (0.01) |
| Tax | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | (0.01) | (0.02) | 0.00 |
Financial Statements
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Revenue | 54.43 | 22.80 | 5.27 |
| Revenue growth | +138.7% | +332.6% | - |
| Other income | 0.30 | 0.04 | 0.07 |
| Total expenses | 54.31 | 22.04 | 5.20 |
| Employee cost | 0.27 | 0.21 | 0.28 |
| EBITDA | 0.12 | 0.76 | 0.07 |
| EBITDA margin | +0.2% | +3.3% | +1.3% |
| Depreciation | 0.38 | 0.45 | 0.21 |
| Interest | 0.11 | 0.29 | 0.14 |
| Profit before tax | (0.07) | 0.06 | (0.21) |
| Tax | (0.13) | 0.07 | 0.01 |
| Net profit | 0.16 | (0.03) | (0.22) |
| Net profit margin | +0.3% | -0.1% | -4.2% |
| EPS (₹) | 0.07 | 0.00 | 0.00 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 6.06 | 6.06 | 6.06 |
| Reserves & surplus | 6.85 | 6.81 | 6.81 |
| Shareholders' funds (net worth) | 12.91 | 12.87 | 12.87 |
| Minority interest | 0.00 | 0.00 | 0.00 |
| Secured loans | 2.27 | 1.25 | 0.27 |
| Unsecured loans | 0.00 | 0.93 | 3.23 |
| Total debt | 2.27 | 2.18 | 3.50 |
| Total liabilities | 15.21 | 15.07 | 16.38 |
| Assets | |||
| Gross block | 10.22 | 10.23 | 10.44 |
| Net block | 8.91 | 9.31 | 9.91 |
| Capital work in progress | 0.00 | 0.00 | 0.00 |
| Investments | 1.36 | 2.61 | 0.00 |
| Inventories | 1.39 | 1.49 | 3.41 |
| Sundry debtors | 3.13 | 0.00 | 0.71 |
| Cash & bank balances | 0.41 | 1.36 | 1.95 |
| Loans & advances | 5.92 | 0.98 | 1.23 |
| Total current assets | 10.85 | 3.83 | 7.30 |
| Total current liabilities | 6.00 | 0.65 | 0.88 |
| Net working capital | 4.85 | 3.18 | 6.42 |
| Total assets | 15.21 | 15.07 | 16.38 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Opening cash | 1.35 | 1.95 | 0.00 |
| Net cash from operating activities | (0.44) | 3.55 | 0.00 |
| Net cash from investing activities | 0.00 | (2.53) | 0.00 |
| Net cash from financing activities | (0.50) | (1.61) | 0.00 |
| Net change in cash | (0.95) | (0.59) | 0.00 |
| Closing cash | 0.41 | 1.36 | 1.95 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Growth | |||
| Sales growth | +138.7% | +332.6% | - |
| EBITDA growth | -84.2% | +985.7% | - |
| PBT growth | - | +9998.0% | +9997.0% |
| Net income growth | +633.3% | +86.4% | - |
| Profitability & leverage | |||
| Net income margin | +0.1% | -0.0% | -4.2% |
| Return on capital employed | +1.6% | +2.8% | -0.4% |
| Return on net worth | +1.1% | -0.2% | -1.7% |
| Debt / equity | 0.17 | 0.22 | 0.27 |
| Long-term debt / equity | 0.00 | 0.12 | 0.23 |
| Interest cover | -42.31 | 93.55 | -100.00 |
| Efficiency & per share | |||
| Fixed asset turnover | 5.32 | 2.21 | 0.53 |
| Inventory turnover | 37.80 | 9.31 | 1.64 |
| Debtors turnover | 34.78 | 64.23 | 7.86 |
| EPS (₹) | 0.07 | 0.00 | 0.00 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 21.29 | 21.23 | 21.24 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.18 | 0.00 | 0.28 | 0.07 | 0.50 | 1.59 | 0.07 | 0.21 |
| Revenue growth (YoY) | -64.0% | -100.0% | +300.0% | -66.7% | +72.4% | +2550.0% | - | - |
| Other income | 0.26 | 0.09 | 0.00 | 0.01 | 0.02 | 0.00 | 0.01 | 0.00 |
| Total expenses | 0.22 | 0.15 | 0.41 | 0.09 | 0.60 | 0.94 | 0.06 | 0.22 |
| EBITDA | (0.04) | (0.15) | (0.13) | (0.02) | (0.10) | 0.65 | 0.01 | (0.01) |
| EBITDA margin | -22.2% | - | -46.4% | -28.6% | -20.0% | +40.9% | +14.3% | -4.8% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.22 | (0.06) | (0.13) | (0.01) | (0.08) | 0.65 | 0.02 | (0.01) |
| Tax | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | (0.01) | (0.02) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.44 | 0.63 | 2.93 | 1.27 | 8.44 | 16.76 | 26.89 |
| Revenue growth | +287.3% | -78.5% | +130.7% | -85.0% | -49.6% | -37.7% | - |
| Other income | 0.03 | 0.02 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 2.03 | 0.71 | 3.06 | 1.37 | 8.94 | 16.93 | 26.94 |
| Employee cost | 0.06 | 0.04 | 0.03 | 0.05 | 0.19 | 0.17 | 0.22 |
| EBITDA | 0.41 | (0.08) | (0.13) | (0.10) | (0.50) | (0.17) | (0.05) |
| EBITDA margin | +16.8% | -12.7% | -4.4% | -7.9% | -5.9% | -1.0% | -0.2% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Interest | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.44 | (0.06) | (0.03) | (0.11) | (0.51) | (0.18) | (0.07) |
| Tax | 0.11 | (0.02) | (0.01) | (0.03) | (0.13) | (0.05) | (0.02) |
| Net profit | 0.33 | (0.04) | (0.02) | (0.08) | (0.38) | (0.13) | (0.05) |
| Net profit margin | +13.5% | -6.4% | -0.7% | -6.3% | -4.5% | -0.8% | -0.2% |
| EPS (₹) | 0.53 | (0.08) | (0.04) | (0.13) | (0.61) | (0.21) | (0.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves & surplus | 9.35 | 9.03 | 9.08 | 9.10 | 6.49 | 6.86 | 6.99 |
| Shareholders' funds (net worth) | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.92 | 13.05 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.93 | 13.06 |
| Assets | |||||||
| Gross block | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.22 | 0.22 |
| Net block | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.06 | 0.07 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.94 | 1.94 |
| Inventories | 6.77 | 6.77 | 6.77 | 6.77 | 6.77 | 4.85 | 0.05 |
| Sundry debtors | 3.93 | 3.58 | 3.69 | 4.76 | 4.88 | 13.51 | 18.34 |
| Cash & bank balances | 0.06 | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 |
| Loans & advances | 4.69 | 4.88 | 4.45 | 3.52 | 0.63 | 1.04 | 1.07 |
| Total current assets | 15.45 | 15.30 | 14.99 | 15.15 | 12.34 | 19.48 | 19.57 |
| Total current liabilities | 0.20 | 0.47 | 0.10 | 0.23 | 0.02 | 8.62 | 8.53 |
| Net working capital | 15.25 | 14.83 | 14.89 | 14.92 | 12.32 | 10.86 | 11.04 |
| Total assets | 15.41 | 15.09 | 15.14 | 15.16 | 12.55 | 12.93 | 13.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 | 0.12 |
| Net cash from operating activities | 0.00 | (0.02) | (0.01) | 2.95 | (2.38) | (0.05) | (4.36) |
| Net cash from investing activities | 0.00 | 0.00 | 0.00 | (2.91) | 2.35 | 0.02 | 4.36 |
| Net cash from financing activities | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Net change in cash | 0.00 | (0.02) | (0.01) | 0.04 | (0.03) | (0.03) | (0.01) |
| Closing cash | 0.06 | 0.07 | 0.08 | 0.10 | 0.06 | 0.08 | 0.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +287.3% | -78.5% | +130.7% | -85.0% | -49.6% | -37.7% | - |
| EBITDA growth | +612.5% | +38.5% | -30.0% | +80.0% | -194.1% | -240.0% | - |
| PBT growth | +9998.0% | -100.0% | +72.7% | +78.4% | -183.3% | -157.1% | - |
| Net income growth | +925.0% | -100.0% | +75.0% | +79.0% | -192.3% | -160.0% | - |
| Revenue CAGR (3Y) | +24.3% | -57.9% | -44.1% | -63.9% | -38.5% | -7.2% | +568.5% |
| EBITDA CAGR (3Y) | - | -45.7% | -8.6% | +26.0% | - | - | -43.7% |
| Profitability & leverage | |||||||
| Net income margin | +13.5% | -6.4% | -0.7% | -6.3% | -4.5% | -0.8% | -0.2% |
| Return on capital employed | +2.8% | -0.5% | -0.1% | -0.8% | -3.9% | -1.4% | -0.5% |
| Return on net worth | +2.1% | -0.3% | -0.1% | -0.6% | -2.9% | -1.0% | -0.4% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | -7.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 81.33 | 21.00 | 97.67 | 31.75 | 62.52 | 76.18 | 122.23 |
| Inventory turnover | 0.36 | 0.09 | 0.43 | 0.19 | 1.45 | 6.84 | 53.25 |
| Debtors turnover | 0.65 | 0.17 | 0.69 | 0.26 | 0.92 | 1.05 | 2.43 |
| EPS (₹) | 0.53 | (0.08) | (0.04) | (0.13) | (0.61) | (0.21) | (0.08) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 25.42 | 24.89 | 24.97 | 25.01 | 20.71 | 21.32 | 21.53 |
To see the full year-wise statements and ratios of Prism Medico and Pharmacy Limited, buy the company report.
Board of directors of Prism Medico and Pharmacy Limited
Prism Medico and Pharmacy has 4 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Davender Singh | Director | 31 Jan 2022 | 4 Years 9 Months | Current |
| Pardeep Kumar | Director | 31 Jan 2022 | 4 Years 9 Months | Current |
| Dinesh Kumar | Director | 14 Aug 2023 | 3 Years 3 Months | Current |
| Sakshi Laller | Whole-Time Director | 16 May 2023 | 3 Years 6 Months | Current |
Auditor
Prism Medico and Pharmacy Limited is audited by HARJEET PARVESH & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| HARJEET PARVESH & CO. | FY 2023 | 017437N |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 25.50%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 74.50%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 25.50% | 25.00% | 25.00% | 25.00% |
| Public | 74.50% | 75.00% | 75.00% | 75.00% |
Deals & funding
Prism Medico and Pharmacy Limited has 474 deals on record (474 market trades); the latest was in May 2026.
Deals on record (5 of 474)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2026 | Market trade | ₹63.4 Lakh | Buyer: 4 individuals Seller: Neo Apex Share Broking Services LLP , 2 individuals |
| Mar 2026 | Market trade | ₹9.4 Lakh | Seller: Neo Apex Share Broking Services LLP |
| Mar 2026 | Market trade | ₹1.66 Cr | Buyer: Neo Apex Share Broking Services LLP , Gala Finance and Investment Private Limited Seller: Neo Apex Share Broking Services LLP , 2 individuals |
| Aug 2025 | Market trade | ₹5.8 Lakh | Buyer: Gala Finance and Investment Private Limited Seller: an individual |
| Mar 2025 | Market trade | ₹6.8 Lakh | Buyer: Mukesh Commercial Pvt Ltd Seller: Nopea Capital Services Private Limited |
To see the full deal history of Prism Medico and Pharmacy Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Prism Medico and Pharmacy Limited has 1 court case on record: 1 filed by Prism Medico and Pharmacy. All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Writ petition | Filed by the company against BSE Limited & Anr | Disposed |
To see the full case history of Prism Medico and Pharmacy Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Prism Medico and Pharmacy Limited has 1 MSME Form 1 return on record for the period ending Sep 2019, listing 21 overdue payments to 1 micro and small supplier. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (1 of 1)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ajooni Biotech Limited |
To see the full MSME payment records of Prism Medico and Pharmacy Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Prism Medico and Pharmacy has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 02AAACW0505H1Z0 | Himachal Pradesh | Active | 09 Feb 2022 |
To see the full GST registrations and return filing status of Prism Medico and Pharmacy Limited, buy the company report.
Recent activity
Prism Medico and Pharmacy Limited has 17 board changes on record since 2009: 8 appointments and 9 cessations. The latest: Vishwambhar Dayal Gupta ceased to be Director on 14 Nov 2024.
8 earlier events are in the company report.
News
Frequently asked questions
Prism Medico and Pharmacy is an active public limited company based in Kala Amb, Himachal Pradesh, India. The company works in industrial chemicals, within the chemicals and materials industry. It was incorporated on 22 March 2002 (24+ years old) and is registered under CIN L24100HP2002PLC009299. Listed on BSE: 512217.
Prism Medico and Pharmacy reported revenue of ₹2.44 Cr for FY 2025-26 (up 287.3% YoY) based on standalone financials.
Prism Medico and Pharmacy has 4 current directors:
- Sakshi Laller - Whole-Time Director
- Davender Singh - Director
- Pardeep Kumar - Director
- Dinesh Kumar - Director
The latest financial statements of Prism Medico and Pharmacy on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Prism Medico and Pharmacy is 02AAACW0505H1Z0, registered in Himachal Pradesh. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Prism Medico and Pharmacy is L24100HP2002PLC009299. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Prism Medico and Pharmacy is a listed company as per MCA records. Its shares are listed on BSE (code: 512217).
Prism Medico and Pharmacy has 1 court case on record: 1 filed by the company.
Prism Medico and Pharmacy was incorporated on 22 March 2002, making it 24+ years old. It is registered with the Registrar of Companies, Himachal Pradesh.
Prism Medico and Pharmacy has 474 deals on record (474 market trades); the latest was in May 2026.
Vishwambhar Dayal Gupta ceased to be Director on 14 Nov 2024. Dinesh Kumar was appointed as Director on 14 Aug 2023. Gursimran Singh ceased to be CFO on 16 May 2023. Prism Medico and Pharmacy has 17 board changes on record in total.

